Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges

Abbott Labs (ABT) PT Lowered to $125 at RBC Capital

April 18, 2024 6:19 AM EDT

RBC Capital analyst Shagun Singh lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $128.00) while maintaining a Outperform rating.

The analyst comments "ABT delivered a Q1 Rev/EPS upside of $80MM/$0.03, respectively, and tightened its FY24 guidance range. Despite a strong Q1... More

Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip

April 17, 2024 7:42 AM EDT

Abbott Laboratories (NYSE: ABT) reported better-than-expected first-quarter top and bottom lines and narrowed its earnings guidance for the full fiscal 2024.

Shares fell over 2% in premarket trading Wednesday.

The healthcare company posted earnings per share (EPS) of $0.98, beating the consensus estimate of $0.96. Revenue... More

Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance

April 17, 2024 7:32 AM EDT

Abbott (NYSE: ABT) reported Q1 EPS of $0.98, $0.02 better than the analyst estimate of $0.96. Revenue for the quarter came in at $9.96 billion versus the consensus estimate of $9.89 billion.

GUIDANCE:

Abbott sees FY2024 EPS of $4.55-$4.70, versus the consensus of $4.59.

Abbott... More